Key takeaways
Psychedelics are gaining mainstream acceptance: Growing research and regulatory momentum are pushing psychedelic therapies closer to becoming approved treatments for mental health conditions like depression, anxiety, and PTSD.
Different business models offer unique opportunities: Companies like MindMed focus on drug development, Numinus Wellness provides therapy services, and Compass Pathways leads in clinical trials—offering investors a range of ways to gain exposure to the sector.
High risk, high reward industry: While the potential for groundbreaking treatments is massive, regulatory hurdles, clinical trial outcomes, and funding challenges make psychedelic stocks highly speculative investments, and should not be invested in without exceptionally high tolerance for risk.
3 stocks I like better than the ones on this list.In This Article
- COMPASS Pathways Plc (CMPS)
- Mind Medicine Mindmed Inc (DFTX)
⚠ Volatility Notice: This article contains micro-cap and/or small-cap stocks (under $1B market cap). These companies tend to have lower trading volume and can experience significantly higher price volatility than large-cap stocks. Please exercise additional caution and conduct thorough due diligence before investing.
COMPASS Pathways Plc (NASDAQ: CMPS)
$10.07
Overall Grade5.2 / 10
COMPASS Pathways Plc (NASDAQ: CMPS) is a mental healthcare company dedicated to accelerating patient access to evidence-based psychedelic therapies. The company is primarily focused on developing COMP360, a proprietary formulation of psilocybin, for treatment-resistant depression (TRD) and other mental health conditions...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-1.8
P/B2.3
P/S-
P/FCF-4.7
FCF Yield-21.4%
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)+1.9%
Revenue 5yr-
EPS 5yr+12.1%
FCF 5yr+14.5%
Fundamentals
Market Cap$746M
Dividend Yield-
Operating Margin-
ROE-130.6%
Interest Coverage-
Competitive Edge
- COMP360 psilocybin therapy targets treatment-resistant depression, a $3B+ addressable market with no approved psychedelic competitor. First-mover advantage in FDA-regulated psychedelic therapy creates a regulatory moat that could take competitors 5+ years to replicate.
- COMPASS holds extensive IP around its synthetic psilocybin formulation and the therapeutic delivery model (trained therapists, controlled settings), creating barriers beyond just the molecule itself.
- The mental health crisis and growing acceptance of psychedelic-assisted therapy represent a genuine secular tailwind. FDA Breakthrough Therapy designation for COMP360 in TRD accelerates the regulatory timeline.
- UK-based with global trial infrastructure gives COMPASS optionality across FDA, EMA, and MHRA regulatory pathways. Multi-jurisdiction approval strategy reduces single-regulator dependency.
- Partnership model with therapy centers rather than building owned clinics keeps the asset-light structure intact and allows rapid geographic scaling if approved, avoiding the capital intensity trap.
By the Numbers
- Net cash position of $114.6M ($1.57 cash per share vs. $5.59 stock price) means 28% of market cap is backed by cash, providing roughly 2-3 years of runway at current burn rates near $160M annually.
- EPS losses are narrowing: YoY EPS improvement of 34.3% and 3Y CAGR improvement of 12.7% show the company is bending the cost curve even without meaningful revenue, a sign of R&D spend discipline.
- FCF-to-net-income conversion of 0.54x with zero capex signals a capital-light model. All cash burn is operational (R&D and G&A), not fixed asset investment, which preserves flexibility to scale down if trials fail.
- Analyst consensus projects an inflection to profitability by Y4 (est. EPS +$0.64) with revenue scaling from $0.56M to $963M by Y5. If even partially correct, the current $556M market cap prices in very little of the upside scenario.
- Growth grade of 6.8/10 is the highest category score, reflecting the consensus view that the revenue ramp from COMP360 commercialization could be steep, with Y3-to-Y5 revenue estimates implying a 109% CAGR.
Risk Factors
- Current ratio of 0.77 is below 1.0, meaning current liabilities exceed current assets. For a pre-revenue biotech burning $160M+ annually, this signals a capital raise is likely within 12-18 months, diluting existing holders.
- Negative buyback yield of -25.3% confirms aggressive share dilution. TTM stock-based compensation of $13.6M is enormous relative to zero revenue, effectively transferring value from shareholders to employees and management.
- Negative book value (-$0.55/share) with debt-to-capital at 94% means the balance sheet is technically insolvent on a GAAP basis. Any equity raise will be done from a position of weakness.
- Profitability grade of 0.7/10 is the worst score by far. With ROIC at -617% and ROE at -571%, every dollar of invested capital is being destroyed. This is expected for clinical-stage biotech but the magnitude is severe.
- Only 2 analysts cover revenue estimates and 5 cover EPS. Thin coverage means consensus estimates are fragile and could swing wildly on a single analyst revision, creating false precision in forward models.
Mind Medicine Mindmed Inc (NASDAQ: DFTX)
$20.02
Overall Grade0.0 / 10
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and other novel therapies to address brain health disorders...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-
P/B-
P/S-
P/FCF-
FCF Yield-
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$0M
Dividend Yield-
Operating Margin-
ROE-
Interest Coverage-
Competitive Edge
- MM120 (lysergide d-tartrate) for generalized anxiety disorder has a differentiated mechanism of action versus SSRIs and benzodiazepines. If approved, it would be the first psychedelic-derived therapy for GAD, a market with 6.8M+ U.S. patients and high unmet need.
- FDA Breakthrough Therapy Designation for MM120 in GAD significantly de-risks the regulatory path, enabling rolling review and more frequent FDA interaction, which historically correlates with higher approval probability versus standard review.
- MindMed's focus on session-free or short-session psychedelic models addresses the biggest commercial bottleneck for competitors like MAPS/Lykos (MDMA therapy requires 3 eight-hour sessions), making MindMed's approach far more scalable in real-world clinical settings.
- The company's IP strategy around specific formulations and dosing regimens of known psychedelic compounds creates a defensible position that pure-play psilocybin competitors like Compass Pathways lack, given the composition-of-matter angle on the d-tartrate salt form.
- Growing institutional acceptance of psychedelic medicine, evidenced by state-level legalization in Oregon and Colorado, creates a regulatory tailwind that reduces political risk for FDA approval and commercial launch.
By the Numbers
- With $2.06B market cap and a P/B of 6.2x, the implied tangible book value around $332M suggests MindMed still holds substantial cash reserves from prior capital raises, critical for a pre-revenue biotech where cash runway is the single most important metric.
- The EV/EBITDA of -10.2x, combined with the market cap, implies enterprise value is meaningfully below market cap, confirming a net cash position that extends operational runway without immediate need for dilutive financing.
- At $20.18 per share, the stock has clearly re-rated higher from its historical lows, suggesting the market is pricing in meaningful probability of clinical success, particularly around the MM120 program for generalized anxiety disorder.
Risk Factors
- TTM stock-based compensation of $20.1M is enormous relative to a company with zero revenue. SBC alone likely represents 6%+ of market cap annually, and the negative buyback yield of -0.23% confirms share count is growing, not shrinking. Shareholders are being steadily diluted.
- Negative FCF yield of -6.4% and negative earnings yield of -10.3% mean the company is burning roughly $131M and $212M respectively on a trailing basis. At that burn rate, even a healthy cash position has a finite and calculable expiration date.
- Shareholder yield is deeply negative at -1.2%, combining dilution from SBC, no buybacks, and net debt issuance (debt paydown yield of -0.97%). Every capital return metric is working against existing shareholders simultaneously.
- P/B of 6.2x for a clinical-stage biotech with no approved products means the market is pricing in over $1.7B of intangible pipeline value above book. If the lead program stumbles in Phase 3, that premium evaporates quickly.
- Binary clinical risk is extreme. MindMed's entire valuation hinges on MM120 Phase 3 readouts. A single failed trial could wipe 50-70% of market cap overnight, as seen with Lykos Therapeutics' FDA rejection of MDMA therapy in 2024.
